Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.36 0.73 +1.02%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 5 5 4

+8 more TTM periods

ROE
21.74% 8.08% 7.07% 14.79%
ROA
17.16% 6.41% 5.62% 11.71%
ROIC
14.97% 1.01% (1.71%) 9.98%
Return on Tangible Assets
44.12% 18.63% 16.67% 30.56%
Average Days of Receivables
42.07 33.79 18.54 28.66
Free Cash Flow per Share
1.83 1.01 1.15 1.37
Free Cash Flow
194.62 106.92 120.15 141.79
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026